## REMARKS

This paper is in response to the official action of February 14, 2005. This response is timely filed, as it is accompanied by a petition for automatic extension of time to file in the second moth, and required petition fee.

In the official action, claims 1-35 were pending, and claims 1-13, 28, 29, and 32-35 were allowed. Claims 15-27, 30, and 31, were objected to.

The examiner's attention is directed to the information disclosure statement filed February 4, 2004, prior to the issuance of the outstanding action, as was the German priority document. Consideration and entry of the art submitted in the information disclosure statement are solicited.

It is applicants' intent to file a supplemental information disclosure statement identifying all art by submitted copies of all art identified in the present application. The supplemental information disclosure statement will be filed as soon as possible.

The objections will be addressed in the same order appearing in the action.

The specification has been objected to for failing to provide proper antecedent basis for the claimed subject matter, specifically the amount of claimed stabilizing amount of CaO in claims 12, 13, 25, and 26, and the teaching of size fraction and surface area as recited in claim 27.

In response, please see the modification of the paragraph bridging pages 4 and 5, which now discloses the amount of CaO which can be combined with the leucite glass ceramic powder to obtain a doped leucite glass ceramic powder to make a doped glass ceramic according to claims 25 and 26 of the application. Also, please see the paragraph inserted at page 4 after line 24 of the application, which discloses the characteristics of the doped leucite glass ceramic according to claims 3-14 of the original application. The limitations of claims 12, 13, and 25-27 are all recited in the amended specification.

These amendments are proper and do not introduce new matter, as the amendments are based on the original claims.

An obvious typographical omission has been corrected at page 3, lines 6 and 30, as the amended passage refers to a leucite class ceramic powder according to original claims 1 and 2, and these amendments are further supported by original claim 3 and in the paragraph appearing at page 4, lines 5-8.

Claims 27 depends from claim 15, which has been objected to under 37 C.F.R. § 1.75, along with claims 16-26, 30 and 31. This objection is respectfully traversed.

Regarding the objection of claims 15-26, 30 and 31 under 37 C.F.R. § 1.75 as being duplicates of claims 2-13, 28 and 29, it is submitted that these claims concern different things. Claim 2 concerns a doped leucite glass ceramic with a specific composition which is further presented in claims 3-13. Claims 28 and 29 recite the chemical curing of this kind of doped leucite glass ceramic. On the other hand, claim 15 recites a doped glass ceramic which is made from a leucite glass ceramic powder with a specific composition according to claim 1. The composition of the leucite glass ceramic powder used to make the doped glass ceramic is further recited in claims 16-26. Claims 30 and 31 concern the chemical curing of this kind of doped glass ceramic.

Leucite can contain additional elements like Na, Ca, Ba, Ce, B or Ti, which can be oxidized during the sintering of the doped leucite glass ceramic powder at high temperature. This may slightly increase the amount of Na<sub>2</sub>O, CaO, BaO, CeO<sub>2</sub>, and TiO<sub>2</sub> present in the doped glass ceramic compared to the amount of Na<sub>2</sub>O, CaO, BaO, CeO<sub>2</sub>, and TiO<sub>2</sub> present in the doped leucite glass ceramic powder used to produce the doped glass ceramic, so that the composition of the doped glass ceramic made with the doped leucite glass ceramic powder may differ from the composition of said powder. Therefore the composition of the doped leucite glass ceramic and of the doped glass ceramic may be slightly different. Therefore, it

should be permissible to claim both glass ceramic compositions and their respective chemical curing.

Should the examiner wish to discuss the foregoing or any matter of form in an effort to advance this application toward allowance, he is urged to telephone the undersigned at the indicated number.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

June 14, 2005

By: James P. Zeller,

Reg\No. 28,491

Attorneys for Applicants

6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606-6357 (312) 474-6300